Through an international collaboration, scientists at St. Jude Children's Research Hospital have leveraged data science, pharmacology and structural information to conduct an atomic-level ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C.

Structure Therapeutics (NASDAQ:GPCR) stock is surging today, up 60% after the biotech company reported promising results of its mid-stage trials for its weight loss pills. Indeed, after 12 weeks, ...

G protein-coupled receptors (GPCRs) play a pivotal role in signal transduction and represent attractive targets for drug development. Recent advances in structural biology have provided insights into ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% ...

Fintel reports that on May 2, 2025, Citigroup initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Buy recommendation. As of April 24, 2025, the average one ...

View Structure Therapeutics, Inc. Sponsored ADR GPCR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...

Structure Therapeutics' GLP-1 candidate showed significant reductions in hemoglobin A1c, weight at 12 weeks. 2.8% study discontinuation rate due to adverse events related to study drug in diabetes ...